Seeking Alpha

BofA revises its stance on a pair of hepatitis-C drugmakers, raising Achillion Pharma (ACHN) to...

BofA revises its stance on a pair of hepatitis-C drugmakers, raising Achillion Pharma (ACHN) to Buy and cutting Idenix Pharma (IDIX) to Neutral. The firm is more optimistic on the market potential for ACHN’s hepatitis-C drug combo, and hikes its share price target to $13 from $7. But IDIX faces difficulties after the FDA placed a clinical hold on one of its hep-C treatments. ACHN +13.5%, IDIX -5.5% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|